<unk> , sold under the brand name Truseltiq, is an anti-cancer medication used to treat cholangiocarcinoma (bile duct cancer).<unk>  is a kinase inhibitor targeting the fibroblast growth factor receptors FGFR1, FGFR2 and FGFR3 It was designated an orphan drug by the U.S. Food and Drug Administration (FDA) in 2019, and it was approved for medical use in the United States in May 2021.
Infigratinib
Selpercatinib
Tucatinib
Fostamatinib
Neratinib
Brigatinib
Capmatinib
Lapatinib